<?xml version="1.0" encoding="UTF-8"?>
<p>Children with hepatitis C with persistently elevated serum aminotransferases or those with fibrosis on liver histology should be considered for treatment. Presently available treatments are IFNα or PEG-IFNα and ribavirin. AASLD and NASPGHAN recommend the FDA-approved combination of PEG-IFNα with ribavirin as first-line treatment for children ages 3–17 years [
 <xref ref-type="bibr" rid="CR148">148</xref>–
 <xref ref-type="bibr" rid="CR153">153</xref>].
</p>
